Disclosure: The authors have no financial interest to declare in relation to the content of this article. All authors received an honorarium for attendance at a meeting. This study was supported by Merz Asia-Pacific Pte. Ltd.
Protox (PROTOX Inc., Seoul, Korea) and The Toxin (Jetema Inc., Seoul, Korea).

Increasingly, aesthetic physicians are encountering secondary nonresponse or “toxin resistance” due to neutralizing antibodies (nAbs) against BoNT/A (“anti-BoNT/A”) after treatment for cosmetic indications.15-12 Secondary treatment failure (STF) is defined as an initial response to BoNT/A followed by variable loss of clinical responsiveness15 over time with repeated injections.14 Partial STF (PSTF) is suspected when achieving the same clinical response requires higher doses of BoNT/A (“dose creep”), or the duration of effect is shorter when using the same dose (“interval creep”). A complete lack of clinical response to any amount of BoNT/A is a complete STF (CSTF).

The current testing benchmarks for detecting nAbs to BoNT/A include the mouse protection assay and mouse hemidiaphragm assay.14 Although standard structural immunological binding assays such as enzyme-linked immunosorbent and immunoprecipitation assays have the required sensitivity for BoNT/A antibody detection, they cannot distinguish nonneutralizing antibodies from the nAbs that hinder normal toxin function. We aimed to understand the situation in APAC by reviewing the published evidence on BoNT/A-associated immunogenicity and by surveying APAC physicians’ current practices with BoNT/A. We then convened an APAC virtual meeting on 24 July 2020 to identify knowledge gaps, share real-world experiences and perspectives, and formulate recommendations for the management of toxin resistance.

**METHODS**

Regular botulinum toxin providers in APAC (n = 128; “experts”), comprising dermatologists, plastic surgeons, and aesthetic physicians who were experienced users of BoNT/A and routinely used two or more BoNT/A brands, were surveyed. A SurveyMonkey questionnaire (SurveyMonkey Inc., www.surveymonkey.com) was distributed by email and posed questions on their current practice with BoNT/A, their experiences and beliefs surrounding the issue of treatment failure secondary to nAb formation, their use of BoNT/A in body indications and intradermally (mesotoxin) for skin quality improvements, and their experiences with neurotoxin products from Asia ("Asian neurotoxins"). Thereafter, 38 experts willing to provide real-world insights were invited to a virtual discussion of their survey responses.

**RESULTS**

We emphasize that our survey was neither designed nor powered to form a consensus for specific APAC countries, regions, clinical practices, or preferences. Rather, the responses represent the broad perspectives, clinical issues, and practices related to immunogenicity experienced by the experts. Of the 128 experts surveyed, 38 attended a virtual meeting to discuss their results.

**Secondary Treatment Failure and Neutralizing Antibodies**

Over half (57%) of the experts believe that CSTF or PSTF can occur and suspect that some of their patients currently exhibit PSTF symptoms (Fig. 1). Importantly, 19% of experts who have encountered STF strongly believe that impurities (specifically, complexing proteins, inactivated neurotoxins, flagellins, and bacterial DNA contaminants)15 in BoNT/A preparations are a significant risk factor. While a quarter have not encountered STF, further work is needed to understand whether specific practices or BoNT/A products contributed to this result.

**nAb Testing**

nAb testing is not locally available to most experts (68%; data not shown), yet 83.3% would test patients suspected of PSTF or CSTF (if available in their country). The remaining 16.7% who would not test for nAbs stated that test results would not change their management plans. To manage PSTF or CSTF, the experts may switch to a formulation free of complexing proteins and other impurities to lower the risk of increasing immunogenicity (68% for PSTF, Fig. 2; 39% for CSTF, Fig. 3) or offer treatment holidays (20% for PSTF, Fig. 2; 48% for CSTF, Fig. 3). Few would change to formulations other than incoA (14% for PSTF, Fig. 2; 6% for CSTF, Fig. 3) or increase the dose of their current brand (10% for PSTF, Fig. 2; 8% for CSTF, Fig. 3). This could reflect some patients’ persistent requests for continued treatments.

**Mesotoxin for Reduction of Dynamic Wrinkles**

In descending frequency (Fig. 4), intradermal toxins are applied for facial lifting, hyperhidrosis, pore size reduction, sebum control, reduction of facial redness, acne, and other indications. Notably, 54% of experts believe that intradermal injections are more immunogenic than intramuscular injections (data not shown). This may reflect the understanding that dendritic cells that facilitate antigen capture are predominantly located in the dermis.16 Also, 94% think it is important to use a highly-purified, complexing protein-free BoNT/A with the lowest immunogenicity for intradermal injections.
Body Indications
Nearly all experts (96%) inject BoNT/A into nonfacial areas, including the trapezius and gastrocnemius muscles (data not shown; Fig. 5). Unlike facial indications, body indications are considered more immunogenic (65%), mainly due to the use of larger doses (eg, >100U). Thus, 97.1% consider using a highly-purified preparation with the lowest immunogenicity to be important for nonfacial indications.

APAC Physicians' Experience with Asian BoNT/A Products
Seventy-three percent of experts have used Asian BoNT/A brands, including Botulax (also known as RegenOx, Letybo, or Zentox, 79%; Fig. 6), Meditoxin (also known as Neuronox, Botulift, Cunox, or Siax, 67%), and Nabota (also known as Jeuveau or Nucieva, 44%). Fewer than 20% have used Innotox. Importantly, 88% of experts believe that higher levels of impurities in Asian BoNT/A products increased the risk of STF due to nAb formation (data not shown).

DISCUSSION
Following the survey, the APAC experts discussed their interventions and perspectives on antibody testing, treatment holidays, switching products, intradermal and intramuscular injections, and experience with new Asian BoNT/A products. We stress that due to country-to-country differences, our survey responses are not a consensus of practices or viewpoints. We refrained from making conclusions on specific country practices to avoid misrepresenting our data. Rather, we aimed to provide an overview of BoNT/A-associated immunogenicity across APAC, and the real-world experiences of the Pan-Australasian medical aesthetics community.

As immunogenic consequences were similar across APAC, our findings are not insignificant. They underscore a need for careful toxin selection and physician guidance on strategies to address STF and/or patient insistence on treatment continuance. To identify variable practices, preferences, and specificities between individual regions (eg, East Asia versus Southeast Asia) or countries (eg, Korea versus Taiwan), additional investigations on toxin immunogenicity are needed. A more structured consensus (eg, Delphi consensus) would facilitate clinicians’ understanding of our survey findings and provide practical guidelines. Future studies, in particular longitudinal real-world studies and clinical registries, will complement our data to shed more light on the complex, dynamic and under-studied real-world experience with BoNT/A immunogenicity in aesthetic practice.

The subsequent sections summarize our clinical experiences of toxin immunogenicity, and may not relate directly to each survey question due to the informal nature of our virtual meeting.

CLINICAL PRACTICE WITH INCobotulinumtoxinA
Although APAC experts have similar experiences, their management strategies diverge depending on the availability of alternative products or antibody testing facilities:
1. In Korea, antibody testing is not performed routinely; instead, suspected cases of STF are verified by frontalis testing. As continuous treatment in complete...
nonresponders is ineffective and may even be detrimental, Korean experts advise distinguishing CSTF from PSTF. However, treatment costs and patient insistence on treatment continuance (even if ineffective) often override physician advice or antibody testing results. In one expert’s practice (JY Park), 60%–70% of patients refuse treatment holidays, insist on continuing treatment, and are thus given incoA due to its purity and low immunogenic potential.

2. Malaysian physicians either switch to incoA after confirming that patients can afford treatment continuance, or were offered a 1-year holiday. If clinical response fails to recover, up to 2 additional years of treatment holiday may be recommended.

3. Australian physicians lack access to testing; so clinical management is determined by patient presentation. Some physicians (N Corduff) switch PSTF patients to incoA as nAb titres have been shown to decline despite continuous, three-monthly incoA treatments. For CSTF patients, a holiday is preferred over brand-switching. For those starting to develop PSTF or near-CSTF, advice on increased dose and costs, and reduced treatment efficacy or longevity, is necessary. A different treatment modality (eg, microfocused ultrasound) may be recommended.

4. Over the decade, the number of body treatments increased in some parts of East Asia (notably, Korea and Hong Kong) as patients sought slimmer legs and a “bridal shoulder” to elongate the neck. Although some anti-BoNT/A antibody tests were recently published (R Wanitphakdeedecha), and other experts have developed their own assays (YY Chao), improvements in test accuracy or specificity are needed to differentiate nonneutralizing antibodies from nAbs. It is important to bear in mind that clinical nonresponse might also be due to suboptimal treatment, such as incorrect injection techniques or product reconstitution. Antibody testing is unhelpful in such situations. Nonetheless, if STF is due to nAb formation, nAb detection assays are useful for understanding patient antibody titres. Antibody titres can then be used to estimate the treatment holiday duration because higher titres will require longer treatment.
holidays. Importantly, doctors should switch to a highly-purified BoNT/A formulation that is free of complexing proteins and other impurities before patients develop signs of resistance. In fact, they should consider using a pure formulation with the lowest immunogenicity in treatment-naive patients so as to reduce the risk of STF from the beginning. Anecdotally, to treat PSTF, more experts would switch to incoA, whereas to treat CSTF, more experts advise treatment holidays of 2–2.5 years. To minimize the risk of re-activating the immune system, experts recommend restarting BoNT/A treatment using a pure product without unnecessary bacterial proteins and components.19

Mesotoxin or intradermal BoNT/A were regarded as more immunogenic than conventional intramuscular injections for dynamic wrinkle reduction, partly as relatively higher doses are used (up to 100 units per session). Also, the dermis is highly-populated with antigen-presenting dendritic cells16 with key immunostimulatory functions like antigen capture and presentation to T-lymphocytes. These physiological functions are applied in vaccinology; some vaccines are delivered intradermally to elicit stronger immune responses.20 In body indications, higher doses of BoNT/A (several hundred units) are injected, thus increasing a patient’s exposure to foreign proteins and their risk of nAb formation. Consequently, it is prudent to use a highly-purified BoNT/A preparation containing only the 150-kDa neurotoxin when treating body indications. Doing so over the course of repeated injections minimizes immunogenic risks and ensures the durability and efficacy of long-term treatment outcomes.

Newer toxin formulations from Asian manufacturers are believed to contain higher levels of impurities. Studies on toxin purity levels14,15 correlate with Korean physicians’ anecdotal perceptions of heightened immunogenic risks associated with some toxins from Korea. Importantly, some BoNT/A manufacturers may be confusing and conflating product sterility with toxin purity when discussing these with physicians. Toxin purity should be defined as the absence of unnecessary bacterial components like complexing proteins, inactivated neurotoxin, flagellin, and DNA contaminants.15 Our survey found that, compared with incoA, aboA, and onaA, Botulax was most frequently

---

**Fig. 4.** Intradermal toxin injections are used for several facial indications. Other indications cited were fine wrinkles, a natural or softer muscle relaxation effect, and rosacea.

---

**Fig. 5.** Intradermal toxin injections are used for several nonfacial indications. Other indications cited were hyperhidrosis in the palms, soles, and axillary areas.
used (58.82%), followed by Meditoxin (32.35%), Nabota (5.88%), and Innotox (2.94%) (data not shown). Most felt that muscle paralysis effects were similar (61.76%), 20.59% felt they were stronger, while 17.65% felt they were weaker. The majority (73.53%) also felt that the duration of action was shorter, while 23.53% felt it was similar and 2.94% felt it was longer.

Multiple studies have documented BoNT/A immunogenicity and its clinical implications. 5,14,21–24 Fundamentally, BoNT/A is a foreign antigen capable of inducing nAbs 25,26 that attenuate the toxin’s therapeutic effect. 24 This can lead to partial treatment failure (where the therapeutic effect is reduced in intensity and/or duration) or even complete treatment failure (where no therapeutic effect is detectable). Antibodies were observed to develop gradually in one case study,27 concurrent with a shorter duration of therapeutic effect (“interval creep”) and necessitating a higher dose to achieve the same results (“dose creep”). Most commercial BoNT/A formulations contain adjuvant substances such as hagemagglutinins (in particular, HA33 28), inactivated neurotoxin,1,4 flagellin, 29 and clostridial DNA, 30 which provide “danger” signals by binding to specific receptors on dendritic cells. 21 Activated dendritic cells internalize and process foreign proteins, subsequently presenting parts of the foreign material to helper T-lymphocytes, which then become activated and stimulate B-lymphocyte maturation into plasma cells to produce antibodies. The pure, active, 150-kDa neurotoxin itself is a weak immunogen with no known associated pattern recognition receptors or toll-like receptors on dendritic cells. 31 However, when adjuvants in the preparation are injected alongside the 150-kDa neurotoxin, they can activate dendritic cells that may accidentally internalize the 150-kDa neurotoxin. Activated dendritic cells may thereupon present parts to the 150-kDa molecule to activate helper T-lymphocytes, resulting in nAb production by B-lymphocytes. In APAC, Xeomin is the only commercially-available neurotoxin preparation, which is free of complexing proteins and other impurities of bacterial origin. As Xeomin only contains the active 150-kDa neurotoxin, it is unlikely to provide a “danger” signal to elicit an immune response and, therefore, presents a very low risk of nAb formation. To date, no incidence of Xeomin-related STF due to nAb formation has been observed in treatment-naive patients. As a detailed exploration is beyond the scope of this article, we direct readers to a recent review,32 which discusses immunogenicity due to BoNT/A formulations with or without accessory proteins, and the clinical and nonclinical evidence for this.

Although toxin purity is a critical risk factor in developing STF, other factors to consider include high treatment dosage, cumulative dosage, short inter-injection intervals, booster injections (re-injections) within 3 weeks of the initial injection, and the patient’s immune responsiveness. Globally, BoNT/A is also used for many off-label aesthetic indications such as muscle volume reduction,33 facial shaping,34 and body line contouring.35 Lower dosage (up to 50U) facial injections have been progressively replaced with high dosages (100U or more) for contouring and lifting, masseter and parotid gland reduction (in Korea and Thailand), platysmal band correction, jawline sharpening, and whole face intradermal lifting.36 In the body, BoNT/A is used for trapezius reduction37 and contouring of the upper arm,38 thigh,39 or calf.39 In the practice by one author (JY Park), calf size reduction is performed every 6 months through intramuscular injections, resulting in a cumulative toxin dose of approximately 640U over a 4-year period. However, extremely bulky calves will accumulate 2400U of toxins over just 3 years. Using such large doses may increase the incidence of secondary nonresponsiveness to BoNT/A; so a high index of suspicion for nAb-induced treatment failure must be maintained when there is nonresponsiveness or declining clinical response indicative of “interval creep” and “dose creep” after repetitive treatments.

Moreover, many presumed STF cases may actually be due to BoNT/A being injected at inadequate doses, using an incorrect technique, or being incorrectly stored, handled, or prepared, and not nAb formation. APAC physicians do not routinely test for nAbs to diagnose antibody-induced STF, but should proactively take measures to prevent immunoreactivation and nAb formation. To do so will require a highly-purified toxin formulation, containing only the active 150-kDa molecule, to be chosen as soon as treatment initiation. This is especially important for patients who are toxin-naive, planning to receive large doses during a single session or more frequently.

Fig. 6. Asian BoNT/A toxins used. Other brands cited were Hugel, Lanzox, and Hengli (lanbotulinumtoxina).
than recommended, or for a long period of time. Young patients will also eventually receive a higher cumulative toxin dose over their lifetime. To ensure that only highly-purified BoNT/A formulations are used, clinicians should review and update their understanding of toxin immunogenicity, base their product selection on peer-reviewed scientific data and literature on specific evidence for purity, and refresh their awareness of clinical studies on immunogenicity in aesthetic medicine. Notably, the experts regarded the choice of highly-purified BoNT/A to be a preventative strategy, which preserves the option for the future use of BoNT/A in therapeutic or neurological interventions, if necessary.

CONCLUSIONS

APAC experts have seen an increase in the number of patients presenting with “toxin resistance” or STF due to nAb formation. This has coincided with wider clinical applications for BoNT/A, its use at higher doses, and the emergence of more commercial BoNT/A preparations. Based on their personal clinical observations and published studies on toxin purity levels, experts agreed that most products contain, to varying degrees, unnecessary bacterial components with the potential to stimulate nAb formation. Thus, clinicians should avoid injecting extraneous components that increase the risk of STF, and consider selecting a highly-purified BoNT/A product that is supported by robust, peer-reviewed evidence, to facilitate long-term treatment efficacy and safeguard patient satisfaction.

Je-Young Park, MD
Apkoo-Jung Department
Oracle Dermatology Center
Seoul, South Korea
E-mail: goodmorning26@hanmail.net

REFERENCES

1. Kerscher M, Wanitphakdeedecha R, Trindade de Almeida A, et al. IncobotulinumtoxinA: a highly purified and precisely manufactured botulinum neurotoxin type A. J Drugs Dermatol. 2019;18:52–57.
2. Jeong S. 4 new botulinum toxins to undergo trials in crowded market. Available at https://www.koreabiomed.com/news/articleView.html?idno=7021. Published 2020. Accessed September 28, 2020.
3. Lim J. Wrinkle treatment companies vie to fill hole left by Meditoxin. Available at http://www.koreaherald.com/view.php?ud=20200506000924. Published 2020. Accessed September 28, 2020.
4. Frevert J, Ahn KY, Park MY, et al. Comparison of botulinum neurotoxin type A formulations in Asia. Clin Cosmet Investig Dermatol. 2018;11:327–331.
5. Torres S, Hamilton M, Sanches E, et al. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clin Cosmet Investig Dermatol. 2014;7:11–17.
6. Borodic G. Immunologic resistance after repeated botulinum toxin type A injections for facial rhytides. Ophthal Micr Plast Reconstr Surg. 2006;22:239–240.
7. Dressler D, Wohlfarth K, Meyer-Rogge E, et al. Antibody-induced failure of botulinum toxin A therapy in cosmetic indications. Dermatol Surg. 2010;36(Suppl 4):2182–2187.
29. Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. *J Immunol.* 2010;185:5677–5682.
30. Frevert J, Groenewald C. Presence of clostridial DNA in botulinum toxin products. *Toxicon.* 2015;93(suppl.):S28–S41.
31. Dey AK, Srivastava IK. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. *Expert Rev Vaccines.* 2011;10:227–251.
32. Carr WW, Jain N, Sublett JW. Immunogenicity of botulinum toxin formulations: potential therapeutic implications. *Adv Ther.* 2021;38:5046–5064.
33. Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. *Plast Reconstr Surg.* 2010;125:1693–1705.
34. Klein FH, Brenner FM, Sato MS, et al. Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy. *An Bras Dermatol.* 2014;89:878–884.
35. Seo K. Body contouring with botulinum toxin. In: Seo KK, ed. *Botulinum Toxin for Asians* [Ebook]. 1st ed. Singapore: Springer; 2017:141–157.
36. Goldenberg G, Do T, Dong J, Lanoue J. An update on neurotoxin products and administration methods. Available at https://www.mdedge.com/dermatology/article/111411/aesthetic-dermatology/update-neurotoxin-products-and-administration. Published 2020. Accessed August 2, 2021.
37. Lee JH, Lee KY, Kim JY, et al. Botulinum toxin injection-site selection for a smooth shoulder line: an anatomical study. *Biomed Res Int.* 2017;2017:3092720.
38. Seo KK, Lee W. Medytoxin/Neuronox. In: Carruthers JCA, ed. *Botulinum Toxin.* Philadelphia, Pa.: Elsevier; 2012:52–58.
39. Lee HJ, Lee DW, Park YH, et al. Botulinum toxin A for aesthetic contouring of enlarged medial gastrocnemius muscle. *Dermatol Surg.* 2004;30:867–871; discussion 871.